01-03-2014 | Letter to the Editor
Haplotype analysis of the C677T and A1298C polymorphisms of MTHFR and susceptibility to chronic myeloid leukemia
Published in: Medical Oncology | Issue 3/2014
Login to get accessExcerpt
I have read with great interest the recent study by Khorshied et al. [1], which has been published in the Medical Oncology. The authors investigated the possible association between genetic polymorphisms in methylenetetrahydrofolate reductase (MTHFR; EC: 1.5.1.20; OMIM: 607093) at nucleotides 677 (C677T, rs.1801133) and 1298 (A1298C, rs.1801131) and the risk of chronic myeloid leukemia (CML) in an Egyptian sample. The authors included 97 CML patients and 130 age- and gender-matched healthy controls in their study. They found that there is no significant association between these polymorphisms and the susceptibility to CML. I would like to make a few comments about the study.
Haplotypes
|
Controls
|
Cases
|
χ 2 (df = 1)
|
P value
|
---|---|---|---|---|
677C–1298A
|
0.4880
|
0.5212
|
0.42
|
0.482
|
677T–1298A
|
0.1850
|
0.2262
|
1.16
|
0.279
|
677C–1298C
|
0.2120
|
0.1334
|
4.68
|
0.030
|
677T–1298C
|
0.1150
|
0.1191
|
0.02
|
0.893
|